Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Allergan to drop $300m on AqueSys
Allergan said it agreed to pay $300 million plus milestones to acquire AqueSys and its Xen soft glaucoma stent in an all-cash deal.
The device made by Aliso Viejo, Calif.-based AqueSys is designed to treat glaucoma by shunting intra-ocular fluid from the anterior chamber of the eye into the sub-conjunctival space. The company raised a $43.6 million Series D funding round and closed enrollment in U.S. clinical trial of the Xen Gel stent in January 2014. Read more
2. Penumbra sets terms for $101m IPO
Penumbra set the range for its pending initial public offering, saying it plans to float 3.8 million shares at $25 to $28 apiece.
That works out to a range of $95 million to $106.4 million, $100.7 million at the midpoint. Read more
1. Report: C.R. Bard underrepresented risk of Recovery IVC filter
C.R. Bard may have downplayed the risk associated with its Recovery blood clot filter, according to a new investigation from NBC News.
The Recovery inferior vena cava filter device is designed to catch blood clots in the vascular system before they can reach the heart or lungs. The invesigation reports that 27 deaths and 100s of non-fatal problems related to the device have been reported. Read more